Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.

However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.

This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.

Inclusion Criteria:

• Untreated cervical cancer with FIGO stage Ib-IIb
• Measurable lesions
• Possible to radical hysterectomy
• Age: 18 and older
• Karnofsky Performance Status≥ 70.
• WBC > 3,000/mm³, Hb > 9.0g/dl, Platelet > 100,000 /mm³, SGOT/SGPT < 60 IU/L, T-Bil < 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG
• Written informed consent

Exclusion Criteria:

• Previous history of cancer
• Patients with previous treatment
• Patients without information of clinical risk factors
• Patients who have active infection